Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients
Kin Wah Fung, Seo H Baik, Fitsum Baye, Zhaonian Zheng, Vojtech Huser, Clement J Mcdonald
PLOS ONE, doi:10.1371/journal.pone.0266922
Background Maintenance drugs are used to treat chronic conditions. Several classes of maintenance drugs have attracted attention because of their potential to affect susceptibility to and severity of COVID-19.
Methods Using claims data on 20% random sample of Part D Medicare enrollees from April to December 2020, we identified patients diagnosed with COVID-19. Using a nested case-control design, non-COVID-19 controls were identified by 1:5 matching on age, race, sex, dualeligibility status, and geographical region. We identified usage of angiotensin-converting enzyme inhibitors (ACEI), angiotensin-receptor blockers (ARB), statins, warfarin, direct factor Xa inhibitors, P2Y12 inhibitors, famotidine and hydroxychloroquine based on Medicare prescription claims data. Using extended Cox regression models with time-varying propensity score adjustment we examined the independent effect of each study drug on contracting COVID-19. For severity of COVID-19, we performed extended Cox regressions on all COVID-19 patients, using COVID-19-related hospitalization and all-cause mortality as outcomes. Covariates included gender, age, race, geographic region, low-income indicator, and co-morbidities. To compensate for indication bias related to the use of hydroxychloroquine for the prophylaxis or treatment of COVID-19, we censored patients who only started on hydroxychloroquine in 2020.
Results Up to December 2020, our sample contained 374,229 Medicare patients over 65 who were diagnosed with COVID-19. Among the COVID-19 patients, 278,912 (74.6%) were on at least one study drug. The three most common study drugs among COVID-19 patients were statins 187,374 (50.1%), ACEI 97,843 (26.2%) and ARB 83,290 (22.3%). For all three outcomes (diagnosis, hospitalization and death), current users of ACEI, ARB,
References
Arshad, Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis,
doi:10.1016/j.ijid.2020.06.099Azzato, Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?, Br J Cancer,
doi:10.1038/sj.bjc.6605062Barochiner, Martinez, Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis, J Clin Pharm Ther,
doi:10.1111/jcpt.13246Bikdeli, COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review, J Am Coll Cardiol,
doi:10.1016/j.jacc.2020.04.031Bourinbaiar, Fruhstorfer, The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents, Life Sci,
doi:10.1016/s0024-3205%2896%2900553-xCsizmadi, Collet, Boivin, Bias and Confounding in Pharmacoepidemiology
Cui, Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia, J Thromb Haemost,
doi:10.1111/jth.14830Ferrario, Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Hydroxychloroquine (No Censoring) �,
doi:10.1161/CIRCULATIONAHA.104.510461Fosbol, Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality, JAMA,
doi:10.1001/jama.2020.11301Freedberg, Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study, Gastroenterology,
doi:10.1053/j.gastro.2020.05.053Guo, Zhu, Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis, Hypertension,
doi:10.1161/HYPERTENSIONAHA.120.15572Health Organization, COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers-Scientific Brief
Hoffmann, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell,
doi:10.1016/j.cell.2020.02.052Inama, Coronavirus disease 2019 infection in patients with recent cardiac surgery: does chronic anticoagulant therapy have a protective effect?, J Cardiovasc Med,
doi:10.2459/JCM.0000000000001066Janowitz, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut,
doi:10.1136/gutjnl-2020-321852Keyaerts, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem Biophys Res Commun,
doi:10.1016/j.bbrc.2004.08.085Klok, Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis, Thromb Res,
doi:10.1016/j.thromres.2020.04.041Li, Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China, JAMA Cardiol,
doi:10.1001/jamacardio.2020.1624Permana, In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis, Pharmacol Rep,
doi:10.1007/s43440-021-00233-3Pourhoseingholi, Baghestani, Vahedi, How to control confounding effects by statistical analysis, Gastroenterol Hepatol Bed Bench
Rodrigues-Diez, Statins: Could an old friend help in the fight against COVID-19?, Br J Pharmacol,
doi:10.1111/bph.15166Rosenbaum, Rubin, The Central Role of the Propensity Score in Observational Studies for Causal Effects, Biometrika
Rossi, Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era, Eur J Intern Med,
doi:10.1016/j.ejim.2020.06.006Russo, Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study, Pharmacol Res,
doi:10.1016/j.phrs.2020.104965Sivaloganathan, Ladikou, Chevassut, COVID-19 mortality in patients on anticoagulants and antiplatelet agents, Br J Haematol,
doi:10.1111/bjh.16968Tang, Abnormal coagulation parameters are associated with prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost,
doi:10.1111/jth.14768Tremblay, Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study, Blood,
doi:10.1182/blood.2020006941Vaduganathan, Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMsr2005760Wu, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B,
doi:10.1016/j.apsb.2020.02.008Wyss, Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles, Epidemiology,
doi:10.1097/EDE.0000000000001107
